Cellectar Biosciences names SVP, corporate development and operations
Mr. Longcor brings more than 20 years of pharmaceutical and biotech experience to Cellectar, and during that time was either responsible for or participated in more than 40 collaborations.
Prior to joining the company, he served as chief business officer for Avillion LLP, where he was responsible for executing the company's unique co-development partnership strategy.
Prior to Avillion, he was vice president of corporate development for Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics) where he was responsible for identifying and concluding several critical collaborations for the company, including a discovery collaboration with Sanofi Aventis.
Prior to Rib-X, Mr. Longcor held key positions in several small to midsized biotech companies where he was responsible for business development, strategic planning and operations.
He holds a B.S. from Dickinson College, an M.S. from Boston University School of Medicine and an M.B.A. from Saint Joseph's University's Haub School of Business. ■
LATEST MOVES FROM Wisconsin
- Jason Industries appoints Brian K. Kobylinski to board
- A. O. Smith appoints David R. Warren as GM of several markets
- A. O. Smith elects Kevin J. Wheeler to board
- Kohl’s appoints Bruce H. Besanko as CFO
- Schneider National appoints James R. Giertz as director
More inside POST
FAW recalls faulty Mazda cars in China Companies